

Decreased microRNA-132 and its function in human non-small cell lung cancer

XIYU LIU¹, SONG YAN², CHANGYAN PEI³ and YOUBIN CUI¹

¹Department of Chest Surgery, The First Bethune Hospital of Jilin University, Changchun, Jilin 130000;

²Department of Chest Surgery, The Cancer Hospital of Jilin Province, Changchun, Jilin 130000;

³Department of Medical Administration, Jilin Province People's Hospital, Changchun, Jilin 130000, P.R. China

Received April 10, 2014; Accepted December 17, 2014

DOI: 10.3892/mmr.2015.3222

Abstract. MicroRNA-132 (miR-132) has been shown to be dysregulated in certain types of human malignancies and is associated with tumor progression. However, its function in non-small cell lung cancer (NSCLC) and whether it is differentially expressed in this disease, remain unclear. Thus, the aim of the present study was to investigate the effects of miR-132 on NSCLC tumorigenesis and progression. Using reverse transcription-quantitative polymerase chain reaction, miR-132 expression was detected in NSCLC cell lines and primary tumor tissues. The association between miR-132 expression, and clinicopathological factors and prognosis was assessed using statistical analysis. An MTT assay, flow cytometry, Transwell invasion assays and scratch migration assays were conducted in order to examine the proliferation, apoptosis, invasion and migration of NSCLC cells that had been transfected with miR-132 mimics or inhibitors. The results showed that miR-132 expression levels were significantly downregulated in NSCLC cells compared with that in corresponding non-cancerous lung tissues ($P < 0.001$). In addition, reduced miR-132 expression was significantly associated with lymph node metastasis ($P = 0.003$), an advanced tumor-node-metastasis stage ($P < 0.001$) and shorter overall survival ($P < 0.001$). Multivariate regression analysis confirmed that downregulation of miR-132 was an independent predictor of prognosis. Furthermore, transfection of miR-132 mimics into the NSCLC cells reduced cell proliferation, invasion and migration, and

promoted cell apoptosis. These findings indicate that miR-132 may be a novel diagnostic and prognostic marker, as well as a potential target for molecular therapy in NSCLC.

Introduction

Lung cancer is the leading cause of cancer-related mortality worldwide (1). Despite advances in the fields of oncology and surgery, the prognosis of lung cancer has not improved significantly over a number of decades (2). Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. As with other types of cancer, the development of NSCLC is a multistep process, which involves the accumulation of genetic and epigenetic changes. However, to date, the complex molecular mechanisms underlying NSCLC carcinogenesis and progression remain poorly understood, and biomarkers have not been identified to detect NSCLC at an early stage. Therefore, it is important to detect novel markers for NSCLC, which are able to accurately identify biological characteristics of tumors, improve therapeutic strategies and predict clinical outcome.

MicroRNAs (miRNAs) are single-stranded, small noncoding RNAs that are 18-25 nucleotides in length (3). They negatively regulate gene expression through base-pairing to the 3'-untranslated region (UTR) of target messenger RNA (mRNA), resulting in the inhibition of translation and mRNA degradation (4,5). Beyond involvement in diverse biological processes, including cell growth, apoptosis, development, differentiation and endocrine homeostasis (6), emerging evidence indicates that the deregulation or dysfunction of miRNAs contribute to human carcinogenesis and cancer progression (7-9). miRNAs may act as either oncogenes or tumor suppressors according to the function of the target gene. In terms of NSCLC, *in vitro* functional assays have shown that miR-31 and miR-196 promote the proliferation, invasion and migration of cancer cells (10,11). Clinical analysis demonstrated that decreased miR-375 and increased miR-21 expression in NSCLC tissues are associated with advanced clinical stage and poor prognosis (12,13). Furthermore, Bian *et al* (14) reported that the upregulation of miR-451 sensitized A549 NSCLC cells to cisplatin. Wang *et al* (13) demonstrated that knock-down of miR-21 increased the radiosensitivity of A549 cells. These findings indicate that miRNAs may act as diagnostic

Correspondence to: Dr Youbin Cui, Department of Chest Surgery, The First Bethune Hospital of Jilin University, 71 Xinminda Street, Changchun, Jilin 130000, P.R. China

E-mail: doccuiyb@163.com

Dr Changyan Pei, Department of Medical Administration, Jilin Province People's Hospital, 1183 Gongnong Street, Changchun, Jilin 130000, P.R. China

E-mail: doccuiyb2@163.com

Key words: microRNA-132, non-small cell lung cancer, reverse transcription-quantitative polymerase chain reaction, prognosis, proliferation, apoptosis

and prognostic markers, as well as potential therapeutic targets in human NSCLC.

miR-132 is known to be a cancer-related miRNA. As a member of the miR-212/132 family, miR-132 has been reported to be involved in the development of a variety of carcinomas, either as a repressor or a promoter. It was shown to be upregulated and to function as an oncogene in squamous cell carcinoma of the tongue (15), colorectal cancer (16), pancreatic cancer (17), hemangioma (18) and chronic lymphocytic leukemia (19). By contrast, it was reported to be downregulated and to function as a tumor suppressor in hepatocellular carcinoma (20), prostate cancer (21), ductal carcinoma *in situ* of breast (22) and osteosarcoma (23). However, little is currently known regarding the association between miR-132 dysregulation and the clinicopathological characteristics of NSCLC, and the involvement of miR-132 in NSCLC progression remains to be elucidated. In the current study, miR-132 expression in paired NSCLC and adjacent noncancerous tissues was measured by a reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay. In addition, the clinicopathological and prognostic value of miR-132 expression in patients with NSCLC was analyzed. Finally, the function of miR-132 in NSCLC cells was investigated.

Materials and methods

Patients and tissue samples. One hundred and nine pairs of primary NSCLC and adjacent noncancerous tissues were collected at the time of surgery from patients who underwent surgical resection at The First Bethune Hospital of Jilin University (Jilin, China) between 1st January, 2005 and 30th December, 2007. All tissues were immediately frozen in liquid nitrogen and stored at -80°C until use. None of the patients had undergone chemotherapy or radiotherapy prior to surgery. Clinicopathological information is shown in Table I. Clinical stages of NSCLC was defined using the tumor-node-metastasis (TNM) staging system (24), which is based on the size of primary tumor (T), whether tumor cells have spread to nearby lymph nodes (N), and whether tumor metastasis (M) has occurred. All of the patients received follow-up periodically (every three months following surgery). Overall survival (OS) was defined as the time from primary surgery until the patient was deceased. For living patients, the date of last follow-up was used. The study was approved by the Research Ethics Committee of The First Bethune Hospital of Jilin University (Jilin, China), and written informed consent was obtained from all patients.

Cell lines and culture conditions. Four NSCLC cell lines (A549, H460, 95D and H358) and the non-cancerous 16HBE human bronchial epithelial cell line were purchased from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in RPMI-1640 medium (Invitrogen Life Technologies, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS; Corning, Inc., Tewksbury, MA, USA), 100 U/ml penicillin and 100 µg/ml streptomycin (Corning, Inc.) in humidified air at 37°C with 5% CO₂.

RNA extraction and RT-qPCR. Total RNA was isolated using TRIzol[®] reagent (Invitrogen Life Technologies, Carlsbad, CA,

USA) according to the manufacturer's instructions. Reverse transcription was conducted from an initial quantity of 100 ng of total RNA using the looped primers (Applied Biosystems, Grand Island, NY, USA). qPCR was performed using the standard Taqman MicroRNA assays (Applied Biosystems) protocol on an ABI7500 real-time PCR detection system (Applied Biosystems) under the following conditions: 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 60 sec. U6 small nuclear RNA was used as an internal control. The RT primers were 5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAGAATTG-3' for miR-132 and 5'-TGGTGTCTGGAGTCG-3' for U6. The PCR primers for mature miR-132 and U6 were as follows: Forward: 5'-GCCCTGATTGTCCAAACGC-3' and reverse: 5'-GTGCAGGGTCCGAGGT-3' for miR-132; and forward: 5'-CTCGCTTTCGGCAGCACACA-3' and reverse: 5'-AACGCTTACGAATTTGCGT-3' for U6. The threshold cycle (Ct) was defined as the fractional cycle number at which the level of fluorescence passed a fixed threshold. Each sample was measured in triplicate, and the quantity of miR-132 relative to that of U6 was calculated using the equation $2^{-\Delta Ct}$, where $\Delta Ct = (Ct^{miR-132} - Ct^{U6})$.

Cell transfection. For RNA transfection, cells were seeded at a density of 1×10⁵/ml (0.5 ml/well) into each well of 24-well plates and incubated overnight. Cells were then transfected with mature miR-132 mimics, miR-132 inhibitors (anti-miR-132) or negative controls (miR-NC or anti-miR-NC) (all from GenePharma, Shanghai, China) using Lipofectamine 2000 (Invitrogen Life Technologies) according to the manufacturer's instructions.

Cell proliferation assay. Cell proliferation capacity was evaluated using an MTT assay. Cells were seeded into 96-well culture plates at a density of 2,000 cells in 200 µl per well and incubated at 37°C following transfection. MTT (100 µl) solution (0.5 mg/ml; Sigma-Aldrich, St. Louis, MO, USA) was added to each well and the cells were incubated for a further 4 h. The medium was then replaced with 150 µl dimethyl sulfoxide (Thermo Fisher Scientific, Loughborough, UK). Spectrometric absorbance at 490 nm was measured using a BioTek[™] ELx800[™] Absorbance Microplate reader (Thermo Fisher Scientific). Cell proliferation was assessed daily for four consecutive days, and the MTT assay was repeated three times.

Detection of apoptosis by flow cytometry. Apoptosis was detected using flow cytometric analysis. Briefly, the cells were washed and resuspended at a concentration of 1×10⁶ cells/ml. Cells were then stained with Annexin V and propidium iodide, using the Annexin V apoptosis detection kit (BD Biosciences, San Jose, CA, USA). Following incubation at room temperature in darkness for 15 min, the cells were immediately analyzed with a FACScan flow cytometer (BD LSRII; Becton-Dickinson, Franklin Lakes, NJ, USA).

Transwell invasion assay. The invasion assay was performed using 24-well transwell chambers (8 µm; Corning, Inc.). The upper chambers were first covered with 1 mg/ml Matrigel (Corning, Inc.). Cells (1×10⁵) suspended in 200 µl

Table I. Correlation between miR-132 expression and clinicopathological features in non-small cell lung cancer.

Clinicopathological feature	No. of cases	miR-132 expression		P-value
		Low [n, (%)]	High [n, (%)]	
Age (years)				
<60	53	28 (52.8)	25 (47.2)	0.703
≥60	56	27 (48.2)	29 (51.8)	
Gender				
Male	68	33 (48.5)	35 (51.5)	0.694
Female	41	22 (53.7)	19 (46.3)	
Smoking status				
Smokers	62	34 (54.8)	28 (45.2)	0.336
Non-smokers	47	21 (44.7)	26 (55.3)	
Histological grade				
G1+G2	54	24 (44.4)	30 (55.6)	0.252
G3	55	31 (56.4)	24 (43.6)	
T classification				
T1+2	73	34 (46.6)	39 (53.4)	0.310
T3	36	21 (58.3)	15 (41.7)	
N classification				
Positive	77	46 (59.7)	31 (40.3)	0.003
Negative	32	9 (28.1)	23 (71.9)	
TNM stage				
I+II	65	23 (35.4)	42 (64.6)	<0.001
III	44	32 (72.7)	12 (27.3)	

miR-132, microRNA-132; TNM, tumor-node-metastasis.

serum-free RPMI-1640 medium, were seeded into the upper chamber, and 500 μ l RPMI-1640 medium containing 10% FBS was added to the lower chamber. Following a 24 h incubation, cells on the upper surface of the membrane were removed and invaded cells were fixed with 95% ethanol, stained with 0.1% crystal violet (Thermo Fisher Scientific) and counted under a light microscope (AX800; Thermo Fisher Scientific).

Scratch migration assay. A scratch migration assay was also performed in order to confirm the effects of miR-132 on NSCLC cell migration. Once NSCLC cells had been transfected with miR-132 mimics, miR-132 inhibitors or NC, they were grown to ~85% confluence and a scratch in the cell monolayer was made using a cell scratch spatula. Cells were incubated under standard conditions (37°C; humidity, 95%; 5% CO₂) for 24 h. Subsequently, the plates were washed twice with fresh RPMI medium containing 10% FBS and images were captured (CKX41; Olympus Corp., Tokyo, Japan)

Statistical analysis. Statistical analyses were conducted using SPSS software version 16.0 (SPSS Inc, Chicago, IL, USA). Data are expressed as the mean \pm standard deviation. The differences between groups were analyzed using Student's t-test or χ^2 -test. Patient survival curves were estimated by the Kaplan-Meier method. The joint effect of covariables was investigated using the Cox Proportional Hazard Regression

model. P<0.05 was considered to indicate a statistically significant difference.

Results

Decreased expression of miR-132 in NSCLC cell lines and primary tumor samples. The level of expression of miR-132 in primary NSCLCs; corresponding adjacent normal lung tissues; human A549, H460, 95D and H358 NSCLC cell lines; and the normal human 16HBE bronchial epithelial cell line were detected using RT-qPCR and normalized to that of U6 small nuclear RNA. As shown in Fig. 1A, the results demonstrated that miR-132 expression was significantly downregulated in NSCLC tissues (8.3 \pm 2.5) compared with that in corresponding noncancerous tissues (19.3 \pm 3.9; P<0.001). Reduced miR-132 expression was also observed in NSCLC cell lines, compared with that in human normal bronchial epithelial cells (Fig. 1B, P<0.001). As A549 cells exhibited the lowest miR-132 expression, while 95D cells expressed relatively high levels of miR-132 among the four NSCLC cell lines, these cell lines were selected for subsequent experiments involving transfection with mature miR-132 mimics or miR-132 inhibitors.

miR-132 expression and clinicopathological features in NSCLC. The association between miR-132 expression and

Table II. Univariate and multivariate analysis of overall survival in 109 patients with non-small cell lung cancer.

Variable	Univariate log-rank test	Cox multivariable analysis	Relative risk
Age at diagnosis (years)			
<60 vs. ≥60	0.620	-	-
Gender			
Male vs. female	0.450	-	-
Smoking status			
Smoker vs. never smoked	0.390	-	-
Histological grade			
(G1+G2) vs. G3	0.270	-	-
T classification			
T1+2 vs. T3	0.180	-	-
N classification			
Positive vs. negative	0.006	0.022	6.258
TNM stage			
I-II vs. III	<0.001	0.008	13.279
miR-132 expression			
High vs. low	<0.001	0.015	8.326

miR-132, microRNA-132; TNM, tumor-node-metastasis.




Figure 1. Expression of miR-132 in NSCLC tissues and cell lines. The expression levels were measured by reverse transcription-quantitative polymerase chain reaction. (A) miR-132 expression was significantly lower in NSCLC tissues than that in corresponding non-cancerous tissues. miR-132 expression levels were calculated by the $2^{-\Delta\Delta Ct}$ method and normalized to that of U6 small nuclear RNA. (B) miR-132 expression was downregulated in the A549, H460, 95D and H358 NSCLC cell lines, compared with that in the 16HBE normal human bronchial epithelial cell line. miRNA, microRNA; NSCLC, non-small cell lung cancer.




Figure 2. Overall survival curves for two groups defined by low and high expression of miR-132 in patients with NSCLC. Low miR-132 expression levels were significantly associated with poor outcome ($P < 0.001$, log-rank test). miR-132, microRNA-132; NSCLC, non-small cell lung cancer.

certain clinicopathological parameters of NSCLC tissues are summarized in Table I. Using the median miR-132 expression of all 109 patients with NSCLC as a cutoff, the patients were divided into two groups: High miR-132 expression and low miR-132 expression. As shown in Table I, the level of miR-132 expression was lower in samples from patients with lymph node metastasis ($P = 0.003$) and an advanced TNM stage ($P < 0.001$). No significant difference was observed between miR-132 expression and age, gender, smoking status, T stage and tumor differentiation.

Downregulation of miR-132 confers a poor prognosis in patients with NSCLC. The potential for using the level of miR-132 expression to assess prognosis, in terms of OS of patients with NSCLC was also evaluated. Using the Kaplan-Meier method and log-rank test, it was demonstrated




Figure 3. Effects of transfection of miR-132 mimics or inhibitors on cell proliferation in A549 and 95D cells. (A) Reverse transcription-quantitative polymerase chain reaction analysis confirmed increased miR-132 expression in A549 cells transfected with miR-132 mimics, and a decreased miR-132 expression in 95D cells transfected with miR-132 inhibitors, compared with control cells. U6 RNA was used as an internal control. (B) An MTT assay showed that miR-132 reduced A549 cell proliferation *in vitro*, while transfection with miR-132 inhibitors resulted in elevated proliferation of 95D cells. miR-132, microRNA-132; NC, normal control.




Figure 4. Flow cytometric analysis of the effect of alteration of miR-132 expression on cell apoptosis. NC, normal control; miR-132, microRNA-132.

that the survival rate of patients with high miR-132 expression was greater than that of patients with low miR-132 expression ($P < 0.001$; Fig. 2). Furthermore, the survival benefits were also observed in those with negative N classification ($P = 0.006$) and an early TNM stage ($P < 0.001$; Table II).

Multivariate Cox regression analysis involving the significant parameters that were identified, revealed that miR-132 expression [relative risk (RR) 8.326; $P = 0.015$], lymph node metastasis (RR 6.258; $P = 0.022$) and TNM stage (RR 13.279; $P = 0.008$) were independent prognostic markers of OS in patients with NSCLC (Table II).

Effects of miR-132 on cell proliferation, apoptosis, invasion and migration. Finally, the biological role of miR-132 in NSCLC was investigated. In order to produce selective over-expression or downregulation of miR-132, mature miR-132 mimics or miR-132 inhibitors were transfected into A549 and 95D cells. RT-qPCR analysis demonstrated increased miR-132 expression following transfection with miR-132 mimics and decreased miR-132 expression following transfection with miR-132 inhibitors (Fig. 3A). An MTT assay showed that cell proliferation was significantly impaired in A549 cells that were transfected with miR-132 mimics, while the proliferation




Figure 5. (A and B) A Transwell invasion assay demonstrated that upregulation of miR-132 impeded the invasion of A549 cells, while transfection of 95D cells with miR-132 inhibitors promoted cell invasion. miR-132, microRNA-132; NC, normal control.




Figure 6. Scratch migration assay confirmed the inhibitory effect of miR-132 on non-small cell lung cancer cell migration. NC, normal control; miR-132, microRNA-132.

of 95D cells was increased in cells transfected with miR-132 inhibitors compared with that in control cells (Fig. 3B).

Flow cytometry was employed to determine the effect of miR-132 on cell apoptosis. The proportion of apoptotic A549 cells transfected with miR-132 mimics was significantly higher than that in the negative control group. Moreover, downregulation of miR-132 by transfection with anti-miR-132 reduced apoptosis in 95D cells (Fig. 4).

Cell invasion is an important component of cancer progression, and involves the migration of tumor cells into contiguous tissues and the dissolution of extracellular matrix proteins. A Transwell invasion assay was performed in order to investigate whether miR-132 had a direct influence on

NSCLC cell invasion. As shown in Fig. 5, upregulation of miR-132 impeded the invasion of A549 cells compared with that in control cells. Conversely, transfection of 95D cells with anti-miR-132, promoted cell invasion ability. A scratch migration assay confirmed the inhibitory effect of miR-132 on NSCLC cell migration (Fig. 6).

Discussion

Lung cancer is a malignant tumor that is associated with significant morbidity and mortality. It is therefore important to investigate the molecular and cellular mechanisms underlying the development of lung cancer, and to identify novel

genetic or protein markers to enable accurate diagnosis and prognostication. The current study showed that miR-132 was downregulated in NSCLC compared with adjacent noncancerous tissues. In addition, decreased miR-132 expression was significantly correlated with the presence of aggressive clinicopathological features. Moreover, a Kaplan-Meier analysis revealed that patients with NSCLC with low miR-132 expression tend to have a shorter OS. Multivariate Cox regression analysis identified miR-132 expression as an independent prognostic factor for OS in patients with NSCLC. Finally, *in vitro* functional assays demonstrated that modulation of miR-132 expression affected NSCLC cell proliferation, apoptosis, invasion and migration. To the best of our knowledge, this is the first study regarding the clinical significance of miR-132 in NSCLC.

miR-132 is a highly conserved miRNA transcribed from an intergenic region on human chromosome 17 by the transcription factor cAMP response element binding protein. The majority of what is currently known regarding the regulation and biological functions of miR-132 has come from studies performed in a neuronal context (25). Recent studies have also demonstrated that miR-132 may modulate the process of tumorigenesis as well as certain behaviors of cancer cells. For example, the proliferation and colony formation of hepatocellular carcinoma cells were shown to be suppressed by miR-132-mediated inhibition of the Akt-signaling pathway (20). Reduced miR-132 expression in osteosarcoma was associated with advanced clinical stage, the presence of distant metastasis, resistance to chemotherapy, and poorer overall and disease-free survival (23). Formosa *et al* (21) demonstrated a correlation between low miR-132 levels in prostate cancer and lymph node invasion, a high Gleason score and a more advanced tumor stage. Restoration of expression of miR-132 in prostate cancer cells promoted cell death by anoikis, and impeded cell migration and invasion.

In contrast to the antitumor properties mentioned above, miR-132 also functions as an oncogene in a number of types of cancer. miRNA microarray analysis has shown an increased miR-132 expression in chronic lymphocytic leukemia (19), colorectal cancer (16) and squamous cell carcinoma of tongue (15). Park *et al* (17) reported that miR-132 is overexpressed in pancreatic adenocarcinoma tissues and that it targets the retinoblastoma tumor suppressor, Rb1. The authors showed that cell proliferation was enhanced in Panc-1 pancreatic cancer cells transfected with pre-miR-132 oligonucleotides, while antisense oligonucleotides against miR-132 reduced cell proliferation and led to G2/M cell cycle arrest. Anand *et al* (18) demonstrated high miR-132 expression in the endothelium of human tumors and hemangiomas, and identified p120RasGAP as a downstream target gene. Ectopic expression of miR-132 in endothelial cells increased their proliferation and angiogenic capacity *in vitro*. Conversely, vessel-targeted nanoparticle delivery of anti-miR-132 suppressed angiogenesis and decreased tumor burden in an orthotopic xenograft mouse model of human breast carcinoma (22). Thus, miR-132 has diverse functions in cancer pathogenesis and progression, and the precise effects of miR-132 appear to be tumor-specific and perhaps dependent on its target molecules in certain types of cancer.

Although numerous genes have been shown to be targets of miR-132, it is predicted that the average miRNA has >100

targets (26). In addition, more than one miRNA may converge on a single transcript target (27). Therefore, the molecular mechanisms and functional targets of miR-132 in the context of NSCLC require further investigation. Furthermore, the current study was limited due to its retrospective nature, which led to our results being considered exploratory rather than conclusive. The sample size was also relatively small. Further prospective analyses using a larger sample size are required to corroborate the results of the present study.

In conclusion, the results demonstrated that miR-132 is downregulated in NSCLC cell lines and samples from patients with NSCLC. Decreased miR-132 expression was shown to be associated with tumor progression and an adverse prognosis. The regulation of miR-132 expression may affect the biological behavior of NSCLC cells. The current findings demonstrate that miR-132 may be useful as a novel biomarker, in addition to providing a potential therapeutic target in NSCLC.

References

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. *CA Cancer J Clin* 60: 277-300, 2010.
2. Verdecchia A, Francisci S, Brenner H, *et al*: Recent cancer survival in Europe: a 2000-02 period analysis of EURO CARE-4 data. *Lancet Oncol* 8: 784-796, 2007.
3. Osman A: MicroRNAs in health and disease - basic science and clinical applications. *Clinical laboratory* 58: 393-402, 2012.
4. Zhao G, Cai C, Yang T, *et al*: MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. *PLoS One* 8: e53906, 2013.
5. Mendell JT and Olson EN: MicroRNAs in stress signaling and human disease. *Cell* 148: 1172-1187, 2012.
6. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 116: 281-297, 2004.
7. Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. *Dev Biol* 302: 1-12, 2007.
8. Dieckmann KP, Spiekermann M, Balks T, *et al*: MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. *Br J Cancer* 107: 1754-1760, 2012.
9. Takahashi M, Cuatrecasas M, Balaguer F, *et al*: The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. *PLoS One* 7: e46684, 2012.
10. Meng W, Ye Z, Cui R, *et al*: MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. *Clin Cancer Res* 19: 5423-5433, 2013.
11. Liu XH, Lu KH, Wang KM, *et al*: MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5. *BMC Cancer* 12: 348, 2012.
12. Li Y, Jiang Q, Xia N, Yang H and Hu C: Decreased expression of microRNA-375 in non-small cell lung cancer and its clinical significance. *J Int Med Res* 40: 1662-1669, 2012.
13. Wang XC, Wang W, Zhang ZB, Zhao J, Tan XG and Luo JC: Overexpression of miRNA-21 promotes radiation-resistance of non-small cell lung cancer. *Radiat Oncol* 8: 146, 2013.
14. Bian HB, Pan X, Yang JS, Wang ZX and De W: Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). *J Exp Clin Cancer Res* 30: 20, 2011.
15. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP and Wei WI: Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. *Clin Cancer Res* 14: 2588-2592, 2008.
16. Yang L, Belaguli N and Berger DH: MicroRNA and colorectal cancer. *World J Surg* 33: 638-646, 2009.
17. Park JK, Henry JC, Jiang J, *et al*: miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. *Biochem Biophys Res Commun* 406: 518-523, 2011.
18. Anand S, Majeti BK, Acevedo LM, *et al*: MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. *Nat Med* 16: 909-914, 2010.
19. Calin GA, Liu CG, Sevignani C, *et al*: MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. *Proc Natl Acad Sci USA* 101: 11755-11760, 2004.

20. Wei X, Tan C, Tang C, *et al*: Epigenetic repression of miR-132 expression by the hepatitis B virus x protein in hepatitis B virus-related hepatocellular carcinoma. *Cell Signal* 25: 1037-1043, 2013.
21. Formosa A, Lena AM, Markert EK, *et al*: DNA methylation silences miR-132 in prostate cancer. *Oncogene* 32: 127-134, 2013.
22. Li S, Meng H, Zhou F, *et al*: MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation. *Pathol Res Pract* 209: 179-183, 2013.
23. Yang J, Gao T, Tang J, Cai H, Lin L and Fu S: Loss of microRNA-132 predicts poor prognosis in patients with primary osteosarcoma. *Mol Cell Biochem* 381: 9-15, 2013.
24. Groome PA1, Bolejack V, Crowley JJ, *et al*: IASLC International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions: The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. *J Thorac Oncol* 2: 694-705, 2007.
25. Wanet A, Tacheny A, Arnould T and Renard P: miR-212/132 expression and functions: within and beyond the neuronal compartment. *Nucleic Acids Res* 40: 4742-4753, 2012.
26. Brennecke J, Stark A, Russell RB and Cohen SM: Principles of microRNA-target recognition. *PLoS Biol* 3: e85, 2005.
27. Krek A, Grun D, Poy MN, *et al*: Combinatorial microRNA target predictions. *Nat Genet* 37: 495-500, 2005.

RETRACTED